Profound Research’s Post

To me, #humanhealthcare means helping patients and their caregivers have long and healthy lives. Today, I’m proud to share #EisaiOncology ’s new identity: “Science-Driven. Human-Centric.”   This phrase reflects our deep commitment to improving the lives of patients and their loved ones. Coupled with our science-first approach, we are striving toward transformative cancer solutions to accelerate progress in oncology.   To learn more about "Eisai US Oncology and hear from other employees on what hhc means to them, click here: https://lnkd.in/eeDxueSG

This groundbreaking research brings new hope to patients with appendix cancer, offering promising treatment options where there were few before. As studies progress, patients and families can expect more effective, personalized care. More at https://lnkd.in/dSSgQRcc #AppendixCancer #CancerResearch #NewHope #PersonalizedMedicine #TargetedTherapy #MedicalBreakthrough #CancerCare 🌟🧬💊

October is #BreastCancer Awareness Month 💕 NeunerPate is dedicated to standing with those affected by breast cancer—clients, families, and communities alike. This month, we join in the effort to raise awareness, promote early detection, and support ongoing research. Breast cancer impacts millions, but together we can make a difference! Whether it’s offering support to a loved one, scheduling a screening, or contributing to breast cancer research, every action counts. 🙏 • • #NeunerPate #AttorneysAtLaw #LegalCounsel #CorporateLitigation #BusinessLaw #Aviation #MaritimeLaw #EnvironmentalLaw #ClassAction #Municipalities #Appeals #EmploymentLaw #PersonalInjury #WorkersComp #ProductLiability

This groundbreaking research brings new hope to patients with appendix cancer, offering promising treatment options where there were few before. As studies progress, patients and families can expect more effective, personalized care. More at https://lnkd.in/dSSgQRcc #AppendixCancer #CancerResearch #NewHope #PersonalizedMedicine #TargetedTherapy #MedicalBreakthrough #CancerCare 🌟🧬💊

In the world of #cancerresearch and #cancertreatment, the Dana-Farber Cancer Institute is synonymous with #innovation, #healthcareexcellence on every conceivable measure, and a beacon of hope for #cancerpatients. How it responds in the coming days, weeks, and months to this "issue" will be instructive and is being watched by the medical-scientific-research community around the world. We need them to succeed! #researchmatters #sciencematters #integritymatters https://lnkd.in/etjNdAiq

🗓️ Add this to your calendars! You won’t want to miss NCI’s session on Survivorship in Advanced Lung Cancer on June 3 at the American Society of Clinical Oncology (ASCO)'s annual meeting! In this session, you'll hear about how to address the needs of patients who are commonly excluded from clinical trials due to factors such as age and health issues. http://spr.ly/6040eIfgA #ASCO24 #CancerResearch #LCSM

Clinical trials play a crucial role in advancing cancer research and treatment. By participating, you can make a difference for yourself and others. Learn more about how can be part of a clinical trial. Email us: [email protected] or call 804-304-5649 #ClinicalTrialsAwareness #clinicaltrials #CancerAwareness #JoinTheFightAgainstCancer #trialsofcolor

Excited about ASCO's Call-to-Action for Expanding Clinical Trial Access! The American Society of Clinical Oncology (ASCO) issued a call-to-action, and I couldn't be more thrilled! We must break down barriers to clinical trials and ensure more people have an opportunity to participate in clinical research. Action 1: Clarity with the FDA Statement of Investigator (Form 1572) Action 2: Routine Acceptance of Local Laboratory and Imaging Facilities Action 3: Foster Partnerships to Increase Patient and Local Clinical Access to Trials The regulatory pathway isn't the bottleneck. DCT methods have been used in oncology trials for many years. The FDA's recent Decentralized Clinical Trial draft guidance has further cleared the air on key issues like managing Form 1572 and leveraging local facilities. As this article points out, the onus shifts to sponsors and investigators. We must leverage these tools and proactively build community relationships and SOPs to expand trial reach. https://lnkd.in/dGRqaeaJ Kudos to American Society of Clinical Oncology (ASCO) and the task force for highlighting these issues. National Cancer Institute (NCI) FDA R. Donald Harvey, PharmD, FCCP, FHOPA, FASCO Grzegorz Nowakowski Craig Lipset Jonathan Cotliar Science 37

A paper from an ASCO task force published today in Cancer, an American Cancer Society journal, details 3 calls-to-action with practical steps aimed at expanding access to #ClinicalTrials and enabling patients to participate in trials closer to home https://lnkd.in/e_yNEv-e

Yes!!! We so desperately need to foster relationships between academic centers and community facilities to allow for more access to critical research! All oncology patients deserve the opportunity to participate in clinical trials. Many people are unable to participate due to lack of accessibility to a center that is conducting trials. This also contributes to the continued under representation/participation of minorities. Glad to see this! #askmeaboutclinicaltrials #oncologyresearch #oncology #clinicalresearch